Effect of β-lactamase detection on reducing the incidence of antibiotic-associated diarrhea in children with severe bacterial pneumonia
XIANG Yun1, WANG Zai-Hua2, CAI Ping2, ZHANG Zhen1
Department of Laboratory Medicine, Wuhan Medical and Health Center for Women and Children, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430016, China
Abstract：Objective To study the effect of β-lactamase (BLs) detection and β-lactam/β-lactamase inhibitor (BL/BLI) on the incidence of antibiotic-associated diarrhea (AAD) in children with severe bacterial pneumonia. Methods The clinical data of the children with bacterial severe pneumonia were retrospectively studied. Of all the patients, 248 using amoxicillin/clavulanate but without BLs detection and 323 using amoxicillin (BLs negative) or amoxicillin/clavulanate (BLs positive) were used as the amoxicillin group; 208 patients using piperacillin/tazobactam but without BLs detection and 291 patients using piperacillin (BLs negative) or piperacillin/tazobactam (BLs positive) were used as the piperacillin group; and 191 patients using cefoperazone/sulbactam but without BLs detection and 341 patients using cefoperazone (BLs negative) or cefoperazone/sulbactam (BLs positive) were used as the cefoperazone group. The incidence and clinical symptoms of AAD between the undetected and detected BLs patients were compared. Results The incidences of AAD in the amoxicillin, piperacillin and cefoperazone groups without BLs detection groups were significantly higher than those in the corresponding groups with negative or positive results of BLs detection (P P Conclusions It is very important to detect BLs for reducing the incidence and relieving symptoms of AAD in children with severe bacterial pneumonia.
XIANG Yun,WANG Zai-Hua,CAI Ping et al. Effect of β-lactamase detection on reducing the incidence of antibiotic-associated diarrhea in children with severe bacterial pneumonia[J]. CJCP, 2016, 18(10): 1001-1004.
Rashid MU, Rosenborg S, Panagiotidis G, et al. Ecological effect of ceftazidime/avibactam on the normal human intestinal microbiota[J]. Int J Antimicrob Agents, 2015, 46(1): 60-65.
[10]
Dubreuil L, Odou MF. Anaerobic bacteria and antibiotics: What kind of unexpected resistance could I find in my laboratory tomorrow[J]. Anaerobe, 2010, 16(6): 555-559.
[11]
Charteris WP, Kelly PM, Morelli L, et al. Antibiotic susceptibility of potentially probiotic Lactobacillus species[J]. J Food Prot, 1998, 61(12): 1636-1643.
[12]
Masco L, Van Hoorde K, De Brandt E, et al. Antimicrobial susceptibility of Bifidobacterium strains from humans, animals and probiotic products[J]. J Antimicrob Chemother, 2006, 58(1): 85-94.
[13]
Bergogne-Bérézin E. Treatment and prevention of antibiotic associated diarrhea[J]. Intern J Antimicrob Agent, 2000, 16(4): 521-526.
[14]
Toussaint KA, Gallagher JC. β-Lactam/β-Lactamase inhibitor combinations: from then to now[J]. Ann Pharmacother, 2015, 49(1): 86-98.
